Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage
- PMID: 24415445
- DOI: 10.1002/hep.27006
Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage
Abstract
Vasoactive drugs are recommended to be started as soon as possible in suspected variceal bleeding, even before diagnostic endoscopy. However, it is still unclear whether the therapeutic efficacies of the various vasoactive drugs used are comparable. The aim of this prospective, multicenter, randomized, noninferiority trial was to characterize the effects of terlipressin, somatostatin, and octreotide when they are initiated before endoscopic treatment in patients with acute variceal bleeding. Patients with liver cirrhosis and significant upper gastrointestinal bleeding were randomly assigned to receive early administration of terlipressin, somatostatin, or octreotide, followed by endoscopic treatment. Patients with nonvariceal bleeding were excluded after endoscopy. The primary endpoint was 5-day treatment success, defined as control of bleeding without rescue treatment, rebleeding, or mortality, with a noninferiority margin of 0.1. In total, 780 patients with variceal bleeding were enrolled: 261 in the terlipressin group; 259 in the somatostatin group; and 260 in the octreotide group. At the time of initial endoscopy, active bleeding was noted in 43.7%, 44.4%, and 43.5% of these patients, respectively (P=0.748), and treatment success was achieved by day 5 in 86.2%, 83.4%, and 83.8% (P=0.636), with similar rates of control of bleeding without rescue treatment (89.7%, 87.6%, and 88.1%; P=0.752), rebleeding (3.4%, 4.8%, and 4.4%; P=0.739), or mortality (8.0%, 8.9%, and 8.8%; P=0.929). The absolute values of the lower bound of confidence intervals for terlipressin versus somatostatin, terlilpressin versus octreotide, and octreotide versus somatostatin were 0.095, 0.090, and 0.065, respectively.
Conclusion: Hemostatic effects and safety did not differ significantly between terlipressin, somatostatin, and octreotide as adjuvants to endoscopic treatment in patients with acute gastroesophageal variceal bleeding.
© 2014 by the American Association for the Study of Liver Diseases.
Comment in
-
Combination of splanchnic vasoconstrictors and endoscopic band ligation is an effective treatment strategy for acute variceal hemorrhage; but how do we get those drugs approved by the FDA?Hepatology. 2014 Sep;60(3):789-91. doi: 10.1002/hep.27080. Epub 2014 Jul 28. Hepatology. 2014. PMID: 24700393 Free PMC article. No abstract available.
-
Reply: To PMID 24415445.Hepatology. 2015 Aug;62(2):653-4. doi: 10.1002/hep.27646. Epub 2015 May 29. Hepatology. 2015. PMID: 25482652 No abstract available.
-
Lack of difference among vasoconstrictors: Similar effectiveness or similar ineffectiveness?Hepatology. 2015 Aug;62(2):653. doi: 10.1002/hep.27648. Epub 2015 May 28. Hepatology. 2015. PMID: 25482959 No abstract available.
Similar articles
-
Terlipressin vs. octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial.Am J Gastroenterol. 2009 Mar;104(3):617-23. doi: 10.1038/ajg.2008.147. Epub 2009 Feb 17. Am J Gastroenterol. 2009. PMID: 19223890 Clinical Trial.
-
[Comparison of terlipressin and octreotide with variceal ligation for controlling acute esophageal variceal bleeding--a randomized prospective study].Korean J Hepatol. 2006 Sep;12(3):385-93. Korean J Hepatol. 2006. PMID: 16998290 Clinical Trial. Korean.
-
[A prospective study comparing the efficacy of early administration of terlipressin and somatostatin for the control of acute variceal bleeding in patients with cirrhosis].Korean J Hepatol. 2006 Sep;12(3):373-84. Korean J Hepatol. 2006. PMID: 16998289 Clinical Trial. Korean.
-
Somatostatin, somatostatin analogues and other vasoactive drugs in the treatment of bleeding oesophageal varices.Dig Liver Dis. 2004 Feb;36 Suppl 1:S93-100. doi: 10.1016/j.dld.2003.11.017. Dig Liver Dis. 2004. PMID: 15077917 Review.
-
Efficacy of vasopressin/terlipressin and somatostatin/octreotide for the prevention of early variceal rebleeding after the initial control of bleeding: a systematic review and meta-analysis.Hepatol Int. 2015 Jan;9(1):120-9. doi: 10.1007/s12072-014-9594-9. Epub 2014 Dec 5. Hepatol Int. 2015. PMID: 25788386
Cited by
-
Management of Patients With Gastric Varices.Gastroenterol Hepatol (N Y). 2022 Oct;18(10):574-585. Gastroenterol Hepatol (N Y). 2022. PMID: 36397927 Free PMC article.
-
Management of Portal Hypertension.J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1184-1199. doi: 10.1016/j.jceh.2022.03.002. Epub 2022 Mar 21. J Clin Exp Hepatol. 2022. PMID: 35814519 Free PMC article. Review.
-
Recommendations on the Diagnosis and Initial Management of Acute Variceal Bleeding and Hepatorenal Syndrome in Patients with Cirrhosis.Dig Dis Sci. 2019 Jun;64(6):1419-1431. doi: 10.1007/s10620-018-5448-y. Epub 2019 Jan 25. Dig Dis Sci. 2019. PMID: 30684079 Review.
-
Update on the management of gastrointestinal varices.World J Gastrointest Pharmacol Ther. 2019 Jan 21;10(1):1-21. doi: 10.4292/wjgpt.v10.i1.1. World J Gastrointest Pharmacol Ther. 2019. PMID: 30697445 Free PMC article. Review.
-
Development and Validation of a Novel Model for Outcomes in Patients with Cirrhosis and Acute Variceal Bleeding.Dig Dis Sci. 2019 Aug;64(8):2327-2337. doi: 10.1007/s10620-019-05557-y. Epub 2019 Mar 4. Dig Dis Sci. 2019. PMID: 30830520
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical